A growing interest was recently focused on the use of Botulinum neurotoxin serotype A
(BoNT/A) for fighting pain. The aim of this study was to investigate the effects of BoNT/A on …

Neuropathic pain is typified by injuries to the peripheral and central nervous system and
derives from such causes as cancer, diabetes, multiple sclerosis, post-herpetic neuralgia …

Clinical use of neurotoxins from Clostridium botulinum is well established and is
continuously expanding, including in treatment of pain conditions. Background: The …

Botulinum neurotoxin serotype A (BoNT/A) shows antinociceptive properties, and its clinical
applications in pain therapy are continuously increasing. BoNT/A specifically cleaves SNAP …

Over the recent years compelling evidence has accumulated indicating that botulinum
neurotoxin serotype A (BoNT/A) results in analgesic effects on neuropathic as well as …

Botulinum neurotoxin type A (BoNT/A) is one of the most potent toxins known and a potential
biological threat. At the same time, it is among the most widely used therapeutic proteins …

The injection of safe doses of botulinum neurotoxin A (BoNT/A) have been reported to be
useful for the treatment of neuropathic pain, but it is still unknown how functional recovery is …

The action of botulinum neurotoxins (BoNTs) at the neuromuscular junction has been
extensively investigated and knowledge gained in this field laid the foundation for the use of …

Background In addition to inhibition of muscle and glandular hyperactivity, botulinum
neurotoxin (Bo NT) type A also interferes with pain processing. Previously, in a rat model of …

Botulinum neurotoxin (BoNT) is usually used in physiatric practice in the treatment of
spasticity and dystonia. Research involving both animal and human subjects has emerged …